Moderna Stock News

The study found Moderna''s COVID-19 to be the most effective in preventing severe illness and deaths.

Moderna (MRNA) closed as the best performer in the S&P 500 as investors propelled the beaten-down biotech after the company painted an upbeat outlook for its blockbuster COVID-19

Fourth Turning 2022: Bad-Moon Rising Authored by Jim Quinn via The Burning Platform blog, Try to unlearn the obsessive fear of death (and the anxious quest for death avoidance) that pervades linear thinking in nearly every modern society. The ancients knew that, without periodic decay and death, nature cannot complete its full round of biological and social change. Without plant death, weeds would strangle the forest. Without human death, memories would never die, and unbroken habits and customs would strangle civilization. Social institutions require no less. Just as floods replenish soil and fires rejuvenate forests, a Fourth Turning clears out societys exhausted elements and creates an opportunity. Strauss & Howe The Fourth Turning Institutions will be increasingly bossy, limiting personal freedoms, chastising bad manners, and cleansing the culture. Powerful new civic organizations will make judgments about which individual rights deserve respect and which do not. Criminal justice will become swift and rough, trampling on some innocents to protect an endangered and desperate society from those feared to be guilty.

100 "Fringe" Predictions For 2022 Submitted by QTR''s Fringe Finance Having already provided my semi-lengthy look at 22 stocks that I am watching heading into 2022 (you can view that far more serious post here ), I wanted to do something more fun, and less serious to open the new year. Heading into each new year, contained herein are 80 predictions of mine - void of all analysis and disclaiming any and all guarantees that I have any idea what I’m talking about . Absolutely none of these are to be considered life advice, investment advice or solicitations to buy or sell securities, sectors or industries mentioned. Please note that I have personal financial exposure to some elements in this list and that these are nothing more than wild-ass guesses, for fun, of what I think the coming year could bring. This list is for fun only - and is all opinion only. Photo: Diginomica It’ll be fun to look back at these predictions next year, when I make a similar list for 2023. And hey, at the very least, this list will serve as a handy reference guide as to how not worth it a paid subscription to my blog can be!

Moderna <> has staged a sharp rally to lead the components of S&P 500 after the Cambridge, Massachusetts-based biotech raised its guidance for 2022 COVID-19 vaccine sales.Speaking

Moderna Inc. (NASDAQ: MRNA ) shares are trading higher Monday after the company said it expects FY21 product sales of approximately $17.5 billion. Throughout 2021 the company shipped approximately 807 million doses of the Moderna COVID-19 vaccine. About 25% of all doses went to low and middle income countries through direct sales by Moderna and donations from high income countries. Moderna was up 8.25% at $231.53 at the time of publication. Moderna Daily Chart Analysis The price looks to have climbed back higher and is sitting slightly above the higher low trendline again. If the higher low trendline ends up holding as an area Full story available on Benzinga.com

These are the stocks posting the largest moves in midday trading.

The latest estimates from the CDC say the Omicron variant accounts for about 95% of all current COVID-19 cases in the US.

Moderna CEO Stephane Bancel said the omicron specific booster will enter clinical trials soon.

Moderna (MRNA) and Carisma Therapeutics have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor

Collaboration will combine Carisma''s engineered macrophage technology with Moderna''s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna…

During its third-quarter earnings results report, Moderna said commercial booster market sales could be up to $2 billion in the United States in 2022.

High-flying tech and growth stocks were among the most popular Full story available on Benzinga.com

COVID Vaccines Do Disrupt Menstrual Cycles, New Study Reveals Authored by Zachary Stieber via The Epoch Times (emphasis ours), A COVID-19 vaccine is administered in Orange, Calif., on Dec. 16, 2020. (John Fredicks/The Epoch Times) Getting a COVID-19 vaccine has been linked to a change in the menstrual cycle among women, per a new study. Dr. Alison Edelman of the Oregon Health & Science University and other researchers studied cycles among 2,403 vaccinated and 1,556 unvaccinated women and concluded vaccination was associated with a change in cycle length. The change was pegged at under one day; no change in menses length was detected. Researchers said that vaccines that use messenger RNA technologyboth Pfizers and Modernas dotrigger an immune response, which could temporarily affect the hypothalamic-pituitary-ovarian axis function, and the study results support the hypothesis. Our findings are reassuring; we find no population-level clinically meaningful change in menstrual cycle length associated with COVID19 vaccination.